Kiora Pharmaceuticals Inc
KPRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001372514
No open-market purchases or sales by Kiora Pharmaceuticals Inc insiders were filed in the last 90 days; 22 institutions reported holding it in 13F filings for Q2 2026, worth $2.91M in total; no superinvestor holds it.
Other share classesKPHMW
Q1 2026 vs. Q4 2025
How the institutions holding Kiora Pharmaceuticals Inc changed between Q4 2025 and Q1 2026.
All holders in Q1 2026All holders in Q4 2025
| Measure | Q4 2025 | Of which not filed for Q1 2026 | Q1 2026 | Change |
|---|---|---|---|---|
| Holders | 19 | 1 | 18 | 0 |
| Shares | 706.9K | 33.1K | 339.2K | −334.7K (−49.7%) |
| Value | $1.39M | $65.2K | $654.7K | −$672.8K (−50.7%) |
1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (7)
Institutions that held Kiora Pharmaceuticals Inc at the end of Q1 2026 but not at the end of Q4 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Vanguard Capital Management LLC | 19,861 | $38.3K | 0.00% |
| Vanguard Fiduciary Trust Co | 13,030 | $25.1K | 0.00% |
| Two Sigma Securities, LLC | 12,019 | $23.2K | 0.00% |
| Rangeley Capital, LLC | 10,000 | $19.3K | 0.02% |
| Morgan Stanley | 1,408 | $2.72K | 0.00% |
| Vanguard Global Advisers, LLC | 200 | $386 | 0.00% |
| Caitong International Asset Management Co., Ltd | 6 | $12 | 0.00% |
Sold out (7)
Institutions that held Kiora Pharmaceuticals Inc at the end of Q4 2025 and filed for Q1 2026 without it.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Stonepine Capital Management, LLC | 131,144 | $258.4K |
| DRW Securities, LLC | 110,282 | $217.3K |
| Nantahala Capital Management, LLC | 106,156 | $209.1K |
| Alyeska Investment Group, L.P. | 76,904 | $151.5K |
| Renaissance Technologies LLC | 21,200 | $41.8K |
| Miller Wealth Advisors, LLC | 1,000 | $1.97K |
| Bank of America Corp | 29 | $57 |
Not filed for Q1 2026 yet (1)
Institutions that held Kiora Pharmaceuticals Inc at the end of Q4 2025 and haven't filed a 13F for Q1 2026. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Vanguard Group Inc | 33,091 | $65.2K |